- Home
- TRAW vs SBFM Comparison
TRAW vs SBFM Comparison
Compare TRAW & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- SBFM
- Stock Information
- Founded
- TRAW 1998
- SBFM 2006
- Country
- TRAW United States
- SBFM United States
- Employees
- TRAW N/A
- SBFM N/A
- Industry
- TRAW
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- TRAW
- SBFM Health Care
- Exchange
- TRAW NYSE
- SBFM Nasdaq
- Market Cap
- TRAW 7.8M
- SBFM 7.7M
- IPO Year
- TRAW 2013
- SBFM N/A
- Fundamental
- Price
- TRAW $1.40
- SBFM $1.43
- Analyst Decision
- TRAW
- SBFM Strong Buy
- Analyst Count
- TRAW 0
- SBFM 1
- Target Price
- TRAW N/A
- SBFM $15.00
- AVG Volume (30 Days)
- TRAW 3.4M
- SBFM 85.2K
- Earning Date
- TRAW 08-14-2025
- SBFM 08-15-2025
- Dividend Yield
- TRAW N/A
- SBFM N/A
- EPS Growth
- TRAW N/A
- SBFM N/A
- EPS
- TRAW N/A
- SBFM N/A
- Revenue
- TRAW $227,000.00
- SBFM $36,234,578.00
- Revenue This Year
- TRAW $3.81
- SBFM $192.48
- Revenue Next Year
- TRAW $30.43
- SBFM N/A
- P/E Ratio
- TRAW N/A
- SBFM N/A
- Revenue Growth
- TRAW 0.44
- SBFM 35.51
- 52 Week Low
- TRAW $0.97
- SBFM $1.17
- 52 Week High
- TRAW $19.44
- SBFM $9.30
- Technical
- Relative Strength Index (RSI)
- TRAW 42.63
- SBFM 48.48
- Support Level
- TRAW $1.62
- SBFM $1.41
- Resistance Level
- TRAW $1.77
- SBFM $1.58
- Average True Range (ATR)
- TRAW 0.15
- SBFM 0.12
- MACD
- TRAW -0.03
- SBFM -0.01
- Stochastic Oscillator
- TRAW 10.34
- SBFM 18.91
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.